文献速递甲状腺疾病

婴儿新型甲状腺激素受体α基因突变致RTHα的早期诊治

Early Diagnosis and Treatment of an Infant with a Novel Thyroid Hormone Receptor α Gene (pC380SfsX9) Mutation.
PubMed 文献 · Thyroid · 2020-12-11

报道一例10月龄女性患儿,因发育迟缓、肌张力低下、大头畸形和严重便秘就诊,检出新生杂合THRA突变pC380SfsX9,诊断为RTHα。左甲状腺素治疗使T4、T3升高,促甲状腺激素及T3/T4比值下降,外周甲状腺激素作用标志物趋于正常。

要点

  • RTHα可在1岁内起病,表现为发育迟缓、肌张力低下、大头畸形和严重便秘。
  • 新生杂合THRA突变pC380SfsX9导致严重RTHα。
  • 左甲状腺素治疗可改善甲状腺功能指标及外周甲状腺激素作用标志物。

核心结论

  • THRA pC380SfsX9突变导致严重RTHα,左甲状腺素治疗可部分改善甲状腺功能指标及外周甲状腺激素作用标志物。

研究设计与样本

  • 病例报告:1例10月龄女性患儿,因发育迟缓、肌张力低下、大头畸形和严重便秘接受评估。

主要发现

  • 检出新生杂合THRA突变pC380SfsX9。
  • 左甲状腺素治疗后T4、T3升高,促甲状腺激素水平及T3/T4比值下降。
  • 外周甲状腺激素作用标志物呈正常化趋势。

临床怎么用

  • 对婴儿出现发育迟缓、肌张力低下、大头畸形和严重便秘,应警惕RTHα并考虑THRA基因检测。
  • 确诊RTHα后左甲状腺素治疗需监测甲状腺功能指标及外周甲状腺激素作用标志物。

局限性

  • 单例病例报告,无法评估长期疗效及安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to thyroid hormone alpha (RTHα) is caused by mutations in thyroid hormone receptor α (THRA). Little is known about the natural history and treatment of RTHα, and diagnosis before the age of 1 year has not been previously reported. A de novo heterozygous THRA mutation (pC380SfsX9) was identified in a 10-month-old female investigated for developmental delay, hypotonia, macrocephaly, and severe constipation. Treatment with levothyroxine was accompanied by an appropriate rise in thyroxine (T4), triiodothyronine (T3), as well as decrease in thyrotropin levels and in the T3/T4 ratio with a trend toward normalization of peripheral markers of thyroid hormone action. THRA pC380SfsX9 results in extreme RTHα.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Furman AE, Dumitrescu AM, Refetoff S, et al. Early Diagnosis and Treatment of an Infant with a Novel Thyroid Hormone Receptor α Gene (pC380SfsX9) Mutation. Thyroid. 2020. PMID: 33198587. doi:10.1089/thy.2020.0695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。